Edition:
United States

Tamara Mathias

Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.

Twitter handle: @jeffmason1

Jun 22 2018

U.S. medical device firm electroCore IPO price set at $15 per share

(This version of the story has been refiled to correct company designation to electroCore Inc from electroCore Llc in first paragraph)

Jun 14 2018

Kellogg issues massive Honey Smacks cereal recall over Salmonella risk

Kellogg Co said on Thursday it is recalling an estimated 1.3 million cases of its Honey Smacks cereal from more than 30 U.S. states due to the potential for Salmonella contamination, in the latest case of U.S. food products possibly tainted by the illness-causing bacteria.

Jun 14 2018

Hong Kong market could open cash flood gates for U.S. biotechs

When U.S. biotech startup Sorrento Therapeutics named ex-Lehman Brothers executive Jiong Shao as its new finance chief about two months ago, it was widely seen as a move driven by his background in raising capital for Alibaba and Tencent.

Jun 13 2018

FDA finds deficiencies in Mylan's generic Advair; shares fall

Mylan NV said on Wednesday that U.S. health regulators were unable to approve its generic version of GlaxoSmithKline's blockbuster inhaled lung drug Advair for the second time, as they found "minor deficiencies" in the treatment.

Jun 13 2018

Lilly's lupus treatment succeeds in mid-stage trial

Eli Lilly & Co said on Wednesday its drug to treat autoimmune disease lupus met the main goal of a mid-stage trial, positioning the drugmaker to begin a bigger study later this year.

Jun 13 2018

Lilly's lupus treatment succeeds in mid-stage trial

June 13 Eli Lilly & Co said its drug to treat autoimmune disease lupus met the main goal of a mid-stage trial, positioning the drugmaker to begin a bigger study later this year.

Jun 08 2018

Insurer lobby group weighs in on Obamacare individual mandate case

Removing certain provisions tied to the Affordable Care Act, former U.S. President Barack Obama's signature healthcare law, could strike out important consumer protections and potentially harm millions of Americans, a trade association that represents U.S. health insurers said on Friday. | Video

Jun 06 2018

J&J gets $2.7 billion offer for sterilization unit from Fortive

Johnson & Johnson said on Wednesday that Fortive Corp had offered to buy its medical sterilization unit for about $2.7 billion in cash.

Jun 04 2018

FDA approves Mylan drug as first biosimilar to Amgen's Neulasta

Mylan NV on Monday beat a clutch of drugmakers racing to get a biosimilar to Amgen Inc's blockbuster drug, Neulasta, to market, with U.S. health regulators approving its version of the infection-fighting treatment.

May 31 2018

Madrigal Pharma more than doubles after liver drug study success

Madrigal Pharmaceuticals Inc's shares more than doubled after mid-stage trial data showed its lead drug reduced liver fat in patients with fatty liver disease, placing it ahead of larger rivals to tap into a potential market worth $30 billion.

Markets

  • U.S.
  • Europe
  • Asia
  • Sectors

Sector Summary